Element Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Element Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-27,016	Closed	-$150K	–	520
2019 Q1	$150K	Buy	+27,016	New	+$164K	﹤0.01%	785
2018 Q4	–	Sell	-10,147	Closed	-$108K	–	789
2018 Q3	$108K	Buy	+10,147	New	+$116K	﹤0.01%	843

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Element Capital Management's LXRX Position: Q2 2019 in Review

Element Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2019, closing a stake of 27,016 shares — an estimated $150K sold.

Element Capital Management first reported a position in LXRX in Q3 2018 and held it in 2 quarters. The position peaked at $150K in Q1 2019. 109 funds tracked by Wall St. Rank hold LXRX as of Q2 2019.

Element Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Element Capital Management sold 27,016 Lexicon Pharmaceuticals shares in Q2 2019, an estimated $150K.
Element Capital Management first reported a position in Lexicon Pharmaceuticals in Q3 2018 and held it in 2 quarters.
Element Capital Management's Lexicon Pharmaceuticals position peaked at $150K in Q1 2019.
109 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2019.

Based on Element Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.